Pfizer expects its turnover by 2021 will be between US$7,050 and US$72.5 billion. Pfizer had previously planned to enter between US$5,940 and 61.4 billion.
Madrid (EUROPA PRESS)-Pfizer Pharmaceuticals of the United States has raised its annual forecast and expects that the commercialization of the vaccine against COVID-19 jointly developed with Germany’s BioNTech will generate a profit of $26 billion, an increase of 73% over the same period last year. Previously estimated.
In this way, Pfizer will issue invoices in the range of US$70,500 to US$7.250 billion in 2021, while previously it planned to enter US$59,000 to US$6,100 billion.
Similarly, the multinational company raised its earnings per share forecast from the previous US$3.10 to US$3.20 to US$3.55 to US$3.65.
In the first three months of 2021, Pfizer recorded an attributable net profit of US$4.877 billion, an increase of 45.4% compared with the same period last year for the pharmaceutical company.
The multinational company’s turnover from January to March reached 14.582 billion US dollars, an increase of 44.6% over the same period last year.
Specifically, Pfizer’s vaccine business between January and March generated US$4.894 billion, an increase of 204% over the same period last year, including US$3.62 billion from the sale of covid-19 vaccines.
For its part, in the first quarter, Pfizer’s total expenses in the oncology area was US$2.862 billion, an increase of 17.5%, while the internal medicine department’s revenue increased by 11.2% to US$2.594 billion. Revenue in the hospital sector is 12%, which is as high as 23.43 million US dollars.